Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 9/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 5/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.44 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8703967 | 0.95 | CCR5 (0.48) | RXRAPTGER1CYP1A2CCR5HCAR3 | |
| SCHEMBL8701112 | 0.92 | CCR5 (0.46) | RXRAPTGER1CYP1A2CCR5HCAR3 | |
| SCHEMBL8162210 | 0.92 | ALDH1A1 (0.45) | RXRAPTGER1CYP1A2CCR5HCAR3 | |
| SCHEMBL8167295 | 0.92 | PTGER1 (0.46) | RXRAPTGER1CYP1A2CCR5USP28 | |
| SCHEMBL8167606 | 0.91 | CCR5 (0.58) | RXRAPTGER1CCR5 | |
| SCHEMBL6256530 | 0.91 | RXRA (0.51) | RXRAPTGER1CYP1A2CCR5HCAR3 | |
| SCHEMBL7662467 | 0.91 | CCR5 (0.45) | RXRAPTGER1CYP1A2CCR5USP28 | |
| SCHEMBL8161455 | 0.91 | PTGER1 (0.54) | RXRAPTGER1CCR5 | |
| SCHEMBL27406198 | 0.89 | RXRA (0.49) | RXRAPTGER1HCAR3ALDH1A1RAB9A | |
| SCHEMBL8162566 | 0.89 | CCR5 (0.45) | RXRAPTGER1CYP1A2CCR5HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1085663-C | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 2002-05-29 | — | — | CN | claimed |
| EP-0773930-B1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LTD (GB) | 2000-10-11 | — | — | EP | claimed |
| CN-1154106-A | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 1997-07-09 | — | — | CN | claimed |
| US-20130217694-A1 | METHOD OF REDUCING THE SEVERITY OF INFLAMMATORY DERMATOLOGICAL CONDITIONS | ALLERGAN, INC.. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217694-A1 | METHOD OF REDUCING THE SEVERITY OF INFLAMMATORY DERMATOLOGICAL CONDITIONS | ALLERGAN, INC.. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130102612-A1 | TOPICAL DERMAL BRIMONIDINE COMPOSITIONS | ALLERGAN, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102612-A1 | TOPICAL DERMAL BRIMONIDINE COMPOSITIONS | ALLERGAN, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120302574-A1 | Methods of Preventing and Reducing the Severity of Stress-Associated Conditions | ALLERGAN, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302574-A1 | Methods of Preventing and Reducing the Severity of Stress-Associated Conditions | ALLERGAN, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1638569-B1 | USE OF BRIMONIDINE FOR PREVENTING AND REDUCING THE SEVERITY OF STRESS-ASSOCIATED CONDITIONS | ALLERGAN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7977335-B2 | Administering brimonidine; skin disorders; irritable bowel syndrome; dyspepsia; cardiovascular disorders; muscle relaxants | ALLERGAN, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20030078236-A1 | Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003033470-A1 | ARYLSULFANYL AND HETEROARYLSULFANYL DERIVATIVES FOR TREATING PAIN | ALLERGAN, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| CN-1085663-C | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 2002-05-29 | — | — | CN | disclosed |
| CN-1286254-A | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 2001-03-07 | — | — | CN | disclosed |
| EP-0773930-B1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LTD (GB) | 2000-10-11 | — | — | EP | disclosed |
| US-5843942-A | Aromatic amino ethers as pain relieving agents | ZENECA LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| CN-1154106-A | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 1997-07-09 | — | — | CN | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302574-A1 | Methods of Preventing and Reducing the Severity of Stress-Associated Conditions | TNNC1, TPSAB1, TNNI3 | RXRA 3106/4885PTGER1 432/4885CYP1A2 1217/4885 |
| US-20130217694-A1 | METHOD OF REDUCING THE SEVERITY OF INFLAMMATORY DERMATOLOGICAL CONDITIONS | CCL11, BDKRB2, ASAH2 | RXRA 1350/4885PTGER1 273/4885CYP1A2 862/4885 |
| US-20130102612-A1 | TOPICAL DERMAL BRIMONIDINE COMPOSITIONS | BDKRB2, BRD2, ADRB2 | RXRA 2909/4885PTGER1 1522/4885CYP1A2 1237/4885 |
| US-20030078236-A1 | Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain | OPRD1, OPRK1, OPRL1 | RXRA 257/4885PTGER1 198/4885CYP1A2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.